β-cyclodextrin, 3,5-dinitrophenyl

This newest derivative of CYCLOBOND cyclodextrin technology has dinitrophenyl functionality bonded through an ether linkage to the beta-cyclodextrin. In this arrangement, a π-electron sharing system is established with analytes having π-systems (e.g. aromatic rings, carbonyl) in the stereogenic environment. Use of the ether linkage to anchor this π-acidic dinitrophenyl ring results in a very stable system even under strong reversed phase conditions. The acidity of this group is further enhanced with the introduction of the trifluoromethyl group in the aromatic ring. Except in a few cases this stationary phase demonstrates complementary selectivity over the conventional CYCLOBOND stationary phases. In a number of cases, selectivity was demonstrated only on the CYCLOBOND I 2000 DNP phase, for instance, ketorolac and oxazepam. Compounds with multiple ring systems show good selectivity, in most cases. While the CYCLOBOND I 2000 DNP demonstrates selectivity in all three mobile phase conditions, reversed phase, normal phase and polar organic phase, the reversed phase conditions yield the greatest number of separations and highest selectivity. It has also been observed that buffers can have a dramatic effect on selectivity, especially those employing ammonium phosphate.

Bonded phase: Dinitrophenyl modified beta-cyclodextrin
Operating pH range: 3 - 7
Particle diameter: 5 or 10 μm
Pore size: 100 Å

Product #


Particle Size

Length × I.D.

Add to Cart

25101AST Astec® CYCLOBOND® I 2000 DNP Chiral HPLC Guard 5 μm
2 cm × 1 mm
21150AST Supelguard Guard Cartridge Holder